A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.

Trial Profile

A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Exeporfinium chloride (Primary) ; Chlorhexidine
  • Indications Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Destiny Pharma
  • Most Recent Events

    • 17 Feb 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 07 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top